Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Air traffic pollution impacts growth and development of unborn children

A UK academic is calling for a nationwide study into the effects traffic pollution has on asthma sufferers after his own research in Cairo highlighted health problems in children who may even be affected while still in the womb.

6 Jul 2011

Novartis reports NVA237 Phase III trial results against COPD

Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.

30 Jun 2011

Wildfire exposure may increase risk of heart failure

An EPA study published online Monday in Environmental Health Perspectives finds that the 2008 peat bog wildfires in NC led to an increase in emergency room visits for respiratory and cardiovascular effects.

28 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

U.S. FDA approves generic Levaquin for treatment of bacterial infections

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.

21 Jun 2011

Two thirds of women with breast cancer more likely to die from cardiovascular disease

Breast cancer accounts for almost a third of all cancer cases reported in women. However advances in the treatment for breast cancer, and early detection, have improved the chances of survival from the disease.

20 Jun 2011

Mist inhalers increase risk of death in patients with COPD

People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, new Johns Hopkins-led research suggests.

16 Jun 2011

Rotech commences $283.5 million registered exchange offer

Rotech Healthcare Inc., one of the largest providers of home medical equipment and related products and services, announced today that it has commenced a registered exchange offer to exchange up to $283.5 million aggregate principal amount of its Senior Second Lien Notes due 2018 which have been registered under the Securities Act of 1933, as amended for an equal principal amount of its outstanding Senior Second Lien Notes due 2018, which were issued in a private placement.

15 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Tiotropium Respimat inhalers can increase risk of death in patients with bronchitis, emphysema

An inhaler designed to help chronic bronchitis and emphysema sufferers breathe could be significantly increasing their risk of dying, according to new research by the University of East Anglia (UEA) and three US universities.

14 Jun 2011

COPD Foundation to host biannual conference in the U.S. for the first time

Originally hosted in Europe on even calendar years, the COPD Conference series for researchers and healthcare professionals is coming to the U.S. for the first time. The COPD Foundation is hosting the COPD7USA Conference, named after the seventh COPD Conference held last summer in the U.K. COPD7USA will be held on December 3rd and 4th at the Crystal City Gateway Marriott, 1700 Jefferson Davis Highway, Crystal City, VA 22202.

17 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

Study associates VDR gene variant with onset of chronic obstructive pulmonary disease in men

Researchers have linked a variant in the vitamin D receptor gene (VDR) with the onset of chronic obstructive pulmonary disease (COPD) in Caucasian men. The study population consisted of participants in the Veterans Administration Normative Aging Study, a multidisciplinary study of aging that began in 1963.

16 May 2011

Rotech Healthcare first quarter adjusted EBITDA increases 13% to $28.3 million

Rotech Healthcare Inc. today announced financial results for the first quarter ended March 31, 2011.

7 May 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Novartis NVA23 Phase III trial in COPD achieves primary end point

Sosei Group Corporation announces that NVA237, a long-acting muscarinic antagonist being investigated as a once daily treatment for chronic obstructive pulmonary disease, achieved its primary end point in a Phase III study.

19 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011